Advertisement

Topics

Otonomy's OTIVIDEX Produces Positive Results from AVERTS-2 Phase III Trial

15:00 EST 13 Nov 2017 | Drug Discovery Development

The company expects to provide an update from discussions with the FDA during the first quarter of 2018.
Contributed Author: 
Otonomy

Original Article: Otonomy's OTIVIDEX Produces Positive Results from AVERTS-2 Phase III Trial

NEXT ARTICLE

More From BioPortfolio on "Otonomy's OTIVIDEX Produces Positive Results from AVERTS-2 Phase III Trial"

Advertisement
Quick Search
Advertisement
Advertisement